Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Drugs Today., Jul;43(7):461-73 (2007)
Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?
Oncology (Williston Park, N.Y.)., Nov;24(13):1204-12 (2010)
Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.
Cancer Invest., Mar;29(3):214-9 (2011)
A phase I study evaluating ibritumomab tiuxetan (ZevalinÂ®) in combination with bortezomib (VelcadeÂ®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Leuk. Lymphoma., Feb;53(2):254-8 (2012)
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.
Patient Prefer Adherence., 6:239-51 (2012)
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies.
Expert Opin Pharmacother., Nov;7(16):2287-99 (2006)
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature.
Support Cancer Ther., Sep;4(4):188-97 (2007)
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Leuk. Lymphoma., May;50(5):741-8 (2009)
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.
Ann. Oncol., Feb;22(2):405-10 (2011)